Bernard Coupal
Directeur/Membre du Conseil chez CARDIAnove, Inc.
Profil
Dr. Bernard Coupal is President at Transfer Technologies Commercialisation Capital.
He joined the firm in 1997.
Between 1967 and 1986 he filled a number of academic positions at the Université de Sherbrooke and the École Polytechnique de Montréal, and also worked in various capacities with the Montreal consulting firm Lavalin.
From 1986 to 1989, he was the Director General of the National Research Council of Canada's Biotechnology Research Institute.
From 1989 to 1992, he partnered with Normand Balthazard in establishing BioCapital, Québec's first specialized investment fund.
From 1992 to 1997, he was the founding president of Société Innovatech du Grand Montréal, a $350 million fund dedicated to promoting technical investments in the Greater Montreal region.
Dr. Coupal has been active in Québec's financial community for many years.
He combines scientific expertise with an in-depth knowledge of finance.
As a researcher, he holds a number of patents currently in use.
During his years as President and Chief Executive Officer of Société Innovatech du Grand Montréal, he actively participated in the start-up of many biotechnological companies, most notably BioSignal, Nexia Biotechnologies, Cryocath, Geneka Biotechnologies and Neurochem.
Dr. Coupal is a chemical engineer and a graduate of the École Polytechnique de Montréal.
He also holds a Ph.D.
degree in Chemical Engineering from the University of Florida.
Postes actifs de Bernard Coupal
| Sociétés | Poste | Début |
|---|---|---|
CARDIAnove, Inc.
 CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | - |
Anciens postes connus de Bernard Coupal
| Sociétés | Poste | Fin |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | 30/01/2007 |
Procyon Biopharma, Inc.
 Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Directeur/Membre du Conseil | 03/03/2006 |
| Société Innovatech du Grand Montréal | President | 31/12/1996 |
PainCeptor Pharma Corp.
 PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Directeur/Membre du Conseil | - |
Transfer Technologies Commercialisation Capital
 Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | President | - |
Formation de Bernard Coupal
| University of Florida | Doctorate Degree |
| Ecole Polytechnique | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Procyon Biopharma, Inc.
Procyon Biopharma, Inc. Miscellaneous Commercial ServicesCommercial Services Procyon Biopharma, Inc. is a biopharmaceutical company engaged in the discovery and development of innovative cancer therapeutic, screening, and diagnostic products and technologies. Procyon has acquired four technologies of which two are broad platform technologies. These two are Prostate Secretory Protein (PSP94), for the prostate cancer market, and the ANA technology platform, that has been developed to improve the immune system and resistibility of cancer. The company is headquartered in Dorval in Québec, Canada | Commercial Services |
Transfer Technologies Commercialisation Capital
Transfer Technologies Commercialisation Capital Investment ManagersFinance T²C² (Transfer Technologies Commercialisation Capital) is a Montréal-based venture capital partnership. They were founded in 1997. | Finance |
PainCeptor Pharma Corp.
PainCeptor Pharma Corp. Pharmaceuticals: MajorHealth Technology PainCeptor Pharma Corp. operates as a biopharmaceutical company which engages in the development of pharmaceuticals for chronic and acute pain. It offers next generation therapeutic drugs for the treatment of chronic and acute pain. The firms products includes NGF/p75-TrkA, ASIC1a and ASIC3. The company was founded by Louis Lamontagne in 2003 and is headquartered in St-Laurent, Canada. | Health Technology |
| Société Innovatech du Grand Montréal | |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
CARDIAnove, Inc.
CARDIAnove, Inc. Medical SpecialtiesHealth Technology CARDIAnove, Inc. engages in the design and development of medical device technologies for temporary and permanent support of the failing heart to improve the quality of life and prolong life of patients suffering from severe congestive heart failure. The company was founded by Conrad Pelletier and Michel Carrier in 1997 and is headquartered in Montréal, Canada. | Health Technology |
